Tell your provider before you run out, not after.<\/p>\n
That is the single most useful thing here, and it is the step people skip because raising money feels awkward. Providers deal with this constantly, they have options you will not find yourself, and the conversation is considerably more productive while you still have supply than after you have missed three doses.<\/p>\n
If you are paying cash for a compounded preparation, losing insurance may not change your medication cost at all, though your overall budget has changed. If you were using insurance, the picture is different and worth working through properly.<\/p>\n
If you paid cash for compounded medication<\/strong>, your medication cost is the same. What changed is your income, which is a budgeting question rather than an access one.<\/p>\n If you had insurance coverage<\/strong>, you may lose it, and the timing depends on your employer and plan. Coverage frequently continues to the end of the month rather than ending on your last day, which is worth confirming because it affects whether you can get a fill before it lapses.<\/p>\n If you had an HSA or FSA<\/strong>, funds may still be available. Our guide on using an HSA or FSA for Ozempic or compounded semaglutide<\/a> covers what typically qualifies.<\/p>\n COBRA or a marketplace plan<\/strong> may be options. Job loss usually triggers a special enrolment period, which is time-limited, so this is worth looking at early rather than when you get around to it.<\/p>\n Be direct rather than hinting. “I’ve lost my job and I need to work out whether I can continue this” gets you a useful answer.<\/p>\n Worth asking specifically:<\/p>\n That last question matters and it is time-sensitive.<\/p>\n Our guides on how to get semaglutide at a lower cost<\/a> and how to get GLP-1 medications without insurance<\/a> cover the options worth checking before you conclude you cannot continue.<\/p>\n Consider this scenario: a patient loses her job and simply stops reordering, assuming she cannot afford to continue. She does not mention it to her provider. Four months later she has regained a substantial amount of weight and restarting means titrating from a low dose again. A conversation in the first week would have surfaced a cheaper option she did not know existed.<\/p>\n The response worth naming, because it is the common one and it makes things worse.<\/p>\n Do not split doses.<\/strong> Splitting is not a supported approach, has not been studied, and introduces a measurement step that is the documented source of serious dosing errors with this medication.<\/p>\n Do not skip weeks<\/strong> to make a supply last. Inconsistent dosing produces an irregular exposure pattern without meaningfully extending anything.<\/p>\n Do not buy from an unverified source.<\/strong> Financial pressure is exactly what pushes people toward sellers with no licensing and no accountability. Our guide on how to verify a compounding pharmacy is safe and legitimate<\/a> covers what to check.<\/p>\n Do not use expired medication<\/strong> to bridge a gap.<\/p>\n It is not a failure and it is manageable, and there is a right way to do it.<\/p>\n Ask what dose to restart at.<\/strong> Tolerance to gastrointestinal effects fades during a break, so resuming at your previous dose after several weeks off can feel like taking it for the first time. Providers frequently restart lower and titrate back up. Find that out now while you are still in contact.<\/p>\n Expect appetite to return<\/strong>, often noticeably, and expect some weight regain. That is a well-documented pattern rather than a personal failure. Our guides on what happens when you stop taking semaglutide<\/a> and pausing semaglutide or tirzepatide<\/a> cover what to expect and how to limit it.<\/p>\nWhat to ask your provider<\/h2>\n
\n
Do not stretch what you have<\/h2>\n
If you do have to pause<\/h2>\n